B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SLC47A1

MOLECULAR TARGET

solute carrier family 47 member 1

UniProt: Q96FL8NCBI Gene: 5524415 compounds

SLC47A1 (solute carrier family 47 member 1) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SLC47A1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Ondansetron1.614
2Cimetidine1.393
3Irinotecan1.393
4pentamidine1.393
5Ritonavir1.393
6Buspirone0.691
7Chlorhexidine0.691
8Dihydroergotamine0.691
9Domperidone0.691
10Famotidine0.691
11Gabexate0.691
12Sumatriptan0.691
13Topotecan0.691
14Tubocurarine0.691
15Vecuronium Bromide Monoquaternary homolog of PANCURONIUM.0.691

About SLC47A1 as a Drug Target

SLC47A1 (solute carrier family 47 member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented SLC47A1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SLC47A1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.